<DOC>
	<DOCNO>NCT01859962</DOCNO>
	<brief_summary>This study design provide preliminary assessment safety effectiveness combination PPI-668 , BI 207127 faldaprevir , without ribavirin , treatment chronic hepatitis C virus infection .</brief_summary>
	<brief_title>Study PPI-668 , BI 207127 Faldaprevir , With Without Ribavirin , Treatment Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Male female , 18 65 year age ; female childbearing potential , must willing use two nonhormonal method birth control 2 . Body weight great 40 kg less 125 kg 3 . Clinical diagnosis chronic hepatitis C 4 . Treatmentna√Øve hepatitis C : previous treatment interferon , pegylated interferon , ribavirin , telaprevir , boceprevir , investigational therapy hepatitis C 5 . No symptoms sign intercurrent illness Screen ( attributable hepatitis C ) 6 . No clinically significant abnormality 12lead electrocardiogram Screen 7 . Signed informed consent prior trial participation . 1 . Seropositive HIV antibody Hepatitis B Surface Antigen Screen 2 . Liver disease due cause chronic HCV infection 3 . Symptoms sign decompensated liver disease , evidence cirrhosis 4 . Any medical condition may interfere absorption , distribution elimination study drug 5 . Poorly control unstable hypertension Screen . 6 . Clinically significant , unstable cardiovascular pulmonary disease , include cardiovascular pulmonary disease require pharmacologic intervention antihypertensive medication , statin , and/or prophylactic aspirin ( similar anticoagulant ) . 7 . Red blood cell disorder , include ( limited ) : thalassemia major minor , sickle cell anemia . 8 . Diabetes Mellitus treat insulin hypoglycemic agent 9 . History asthma require hospital admission within precede 12 month 10 . History alcohol abuse illicit drug use could interfere patient 's compliance protocol requirement , safety efficacy assessment study 11 . Patients require treatment , study , medication restrict medication list ( provide investigator site file ) , eligible study due consideration possible drug interaction study drug regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Liver disease</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>NS5B polymerase inhibitor</keyword>
	<keyword>NS5A inhibitor</keyword>
</DOC>